1. Serum selenium concentration at diagnosis and outcome in patients with haematological malignancies
- Author
-
Ama Z. S. Rohatiner, Jane Stevens, Jude Fitzgibbon, Simon P. Joel, Christina Sieniawska, Shireen Kassam, Rachel Waters, Silvia Montoto, and Andrew Lister
- Subjects
medicine.medical_specialty ,biology ,Proportional hazards model ,business.industry ,Hazard ratio ,Albumin ,Follicular lymphoma ,Serum albumin ,chemistry.chemical_element ,Hematology ,medicine.disease ,Gastroenterology ,Confidence interval ,Lymphoma ,chemistry ,hemic and lymphatic diseases ,Internal medicine ,Immunology ,medicine ,biology.protein ,business ,Selenium - Abstract
Summary We have previously reported presentation serum selenium level to be predictive of outcome in diffuse large B–cell lymphoma. This has now been studied in a further 430 patients, 163 with acute myeloid leukaemia (AML), 156 with Hodgkin Lymphoma (HL), and 111 with Follicular Lymphoma (FL). Serum selenium was below the UK normal reference range in 45% of patients, and correlated with serum albumin (r = 0·24–0·46, P
- Published
- 2011